CANCER ALLIANCE PUBLISHES IMPORTANT NEW STUDY ON BREAST CANCER AND TRASTUZUMAB ACCESS IN SOUTH AFRICA

Tobeka Daki Trastuzumab Access CampaignThe Cancer Alliance today publishes an important new study BREAST CANCER and HER2+ BREAST CANCER WITH A LOOK AT TRASTUZUMAB ACCESS IN SOUTH AFRICA.

Breast cancer is the most common cancer in South Africa. It is also the second highest cancer killer of our women. At least 1 in 27 women will be diagnosed with breast cancer in their lifetime. Of these 26% will be diagnosed with HER2+ breast cancer. Adjuvant treatment (Treatment that is given in addition to the primary (initial) treatment to maximise its effectiveness) is provided in the form of trastuzumab.

To date only the originator trastuzumab Herceptin® and Herclon® are available in South Africa. The originator product Herceptin® is available in the private sector but remains unaffordable for the majority of women. Secondary patents for this medicine could block the entry of competitor products until 2026.

Click here to read more and download the full report.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

LETS FIGHT TOGETHER

drop us a line